RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN319.98m
- PLN332.91m
- PLN62.25m
Brief: Ryvu Therapeutics Q2 Net Loss Widens To 24.2 Mln Zlotys
Brief: Ryvu Therapeutics Says FDA Lifts Partial Clinical Hold On Rvu120 Phase Ib Study In Acute Myeloid Leukemia And Myelodysplastic Syndrome
Brief: Ryvu Therapeutics Got Full Approval To Conduct Phase I/II Study Of RVU120 In Patients With Relapsed/Refractory Metastatic Or Advanced Solid Tumors In Poland
Brief: Ryvu Therapeutics Says Total Non-Cash Expense From Incentive Programme Will Amount To PLN 51-62 Mln Spread Over 2021-2024
Brief: Ryvu Therapeutics Q1 Net Loss Widens To 13.6 Mln Zlotys
Brief: Ryvu Therapeutics Appoints Vatnak VAT-Ho As Chief Business Officer
Brief: Ryvu Announces Partial Clinical Hold Of Phase Ib Clinical Trial Of RVU120
Brief: Ryvu Therapeutics Signs 18.9 Mln Zloty Grant Deal For Tumor Drug Project
Brief: Ryvu Therapeutics FY Net Loss Narrows To 31.7 Mln Zlotys
Brief: Ryvu Therapeutics Signs Deal With US-based Covance
Brief: Ryvu Therapeutics Says Poland's Medicines Authority Allows For Phase I Trial Of SEL120
Brief: Ryvu Therapeutics 9-Month Net Loss Shrinks To 20.7 Mln Zlotys
Brief: Ryvu Therapeutics Revises Portfolio Of Research Projects
Brief: Ryvu Therapeutics Says SEL24/MEN1703 Administered To First Patient In Europe
Brief: Ryvu Therapeutics Q2 Net Loss Narrows To 4.3 Mln Zlotys
Brief: Ryvu Therapeutics Allots 2.4 Mln Series I Shares At 60 Zloty/Shr
Brief: Ryvu Therapeutics Signs Placement Deal And Starts ABB Process
Brief: Ryvu Therapeutics EGM To Vote On Raising Share Capital
Brief: Ryvu Therapeutics Adopts Strategy For 2020-2022